{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:18:02Z","timestamp":1792793882301,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.metabol.2021.154752","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T23:02:27Z","timestamp":1615503747000},"page":"154752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2422-3041","authenticated-orcid":false,"given":"Stefano","family":"Ciardullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3024-0457","authenticated-orcid":false,"given":"Gianluca","family":"Perseghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154752_bb0005","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2021.154752_bb0010","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2337\/diacare.22.5.756","article-title":"Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study","volume":"22","author":"de Marco","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154752_bb0015","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154752_bb0020","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154752_bb0025","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154752_bb0030","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.metabol.2021.154752_bb0035","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154752_bb0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"Cosentino","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154752_bb0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","article-title":"Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study","volume":"111","author":"Huang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154752_bb0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","article-title":"Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection","volume":"63","author":"Yang","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154752_bb0055","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154752_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2019.02.028","article-title":"Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes","volume":"284","author":"Nascimbeni","year":"2019","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.metabol.2021.154752_bb0065","series-title":"2017: National Health and Nutrition Examination Survey (NHANES)","author":"Centers for disease control and prevention","year":"2017"},{"key":"10.1016\/j.metabol.2021.154752_bb0070","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154752_bb0075","author":"National Center for Health Statistics"},{"key":"10.1016\/j.metabol.2021.154752_bb0080","first-page":"e13","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"24","author":"Grundy","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2021.154752_bb0085","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154752_bb0090","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2021.154752_bb0095","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology."},{"key":"10.1016\/j.metabol.2021.154752_bb0100","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.metabol.2021.154752_bb0105","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154752_bb0110","first-page":"275","article-title":"Effects of rosuvastatin and\/or \u03b2-carotene on non-alcoholic fatty liver in rats","volume":"10","author":"Seif el-Din","year":"2015","journal-title":"Res Pharm Sci"},{"key":"10.1016\/j.metabol.2021.154752_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2014.12.003","article-title":"Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis","volume":"96","author":"Kabel","year":"2015","journal-title":"Prostaglandins Leukot Essent Fat Acids"},{"key":"10.1016\/j.metabol.2021.154752_bb0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2021.154752_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000075","article-title":"Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease","volume":"3","author":"Nascimbeni","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154752_bb0130","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2021.154752_bb0135","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.3748\/wjg.v21.i25.7860","article-title":"Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome","volume":"21","author":"Kargiotis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154752_bb0140","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/ajg.2017.170","article-title":"Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis","volume":"112","author":"Kamal","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.metabol.2021.154752_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Official journal of the American College of Gastroenterology| ACG"},{"key":"10.1016\/j.metabol.2021.154752_bb0150","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.dld.2014.04.002","article-title":"Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals","volume":"46","author":"de Keyser","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2021.154752_bb0155","article-title":"Diabetes liver fibrosis score to detect advanced fibrosis in diabetics with non-alcoholic fatty liver disease","author":"Singh","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2021.154752_bb0160","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology."}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:28:34Z","timestamp":1758428914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":32,"alternative-id":["S0026049521000524"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154752","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154752","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154752"}}